financetom
Business
financetom
/
Business
/
As Trump, Kamala Harris, And Biden Unite Against Nippon Steel's $15B US Steel Acquisition, Japanese Steelmaker Spends $1.3M On Lobbying Efforts
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
As Trump, Kamala Harris, And Biden Unite Against Nippon Steel's $15B US Steel Acquisition, Japanese Steelmaker Spends $1.3M On Lobbying Efforts
Oct 22, 2024 12:58 PM

To secure its proposed acquisition of United States Steel Corporation ( X ) , Japanese steelmaker Nippon Steel ( NISTF ) (OTC:NISTF) has boosted its lobbying spending in Washington.

What Happened: Nippon Steel ( NISTF ) has spent $1.3 million on lobbying between July and September, a substantial increase from the $1.1 million spent in the preceding seven months, according to a disclosure by the firm hired by the Japanese steelmaker.

The company is facing resistance from U.S. lawmakers, who have expressed concerns over the proposed $15 billion acquisition.

Nippon Steel ( NISTF ) hired Akin Gump Strauss Hauer & Feld to lobby on issues related to the merger. The firm disclosed lobbying activities with various government bodies, including the House, Senate, and the Office of the U.S. Trade Representative.

The surge in lobbying spending coincides with a crucial phase for the merger in Washington. President Joe Biden was reportedly set to block the acquisition in September, prompting Nippon Steel’s vice chair to make a last-ditch effort to save the deal.

The Committee on Foreign Investment in the United States (CFIUS) subsequently allowed Nippon Steel ( NISTF ) to refile its bid after the election.

Nippon Steel ( NISTF ) did not immediately respond to Benzinga's request for comment.

See Also: Investors Lost Over 95% Of Their Wealth In This Nvidia-Linked ETF While Jensen Huang-Led Chip Giant Gained 220% In The Past Year: Here’s More

Why It Matters: The increased lobbying expenditure by Nippon Steel ( NISTF ) comes amid strong opposition to the acquisition from both sides of the political spectrum. This move reflects the company’s determination to push through the deal despite the challenges it faces in Washington.

Earlier in September, Democratic presidential candidate Kamala Harris emphasized the importance of maintaining domestic control over steel production, even if it results in job losses. This stance aligns with the concerns expressed by U.S. lawmakers regarding the potential impact of the acquisition on American jobs and national security.

Meanwhile, former President Donald Trump has vowed to block the deal if he is re-elected.

Despite the opposition, Nippon Steel ( NISTF ) secured a favorable arbitration ruling in its $15 billion acquisition of U.S. Steel. The ruling, however, did not change the United Steelworkers’ (USW) opposition to the deal.

Read Next:

Shiba Inu Ready For A Lift-Off To The Moon? Popular Analyst Predicts 50% Surge For Memecoin As Burn Rate Spikes 389%

Image Via Shutterstock

This story was generated using Benzinga Neuro and edited by Kaustubh Bagalkote

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Terns Pharmaceuticals Names Elona Kogan as Chief Legal Officer; CFO Mark Vignola to Leave in 'Planned Transition'
Terns Pharmaceuticals Names Elona Kogan as Chief Legal Officer; CFO Mark Vignola to Leave in 'Planned Transition'
Jul 30, 2024
04:45 AM EDT, 07/30/2024 (MT Newswires) -- Terns Pharmaceuticals ( TERN ) said late Monday that it appointed Elona Kogan as its chief legal officer while announcing changes to its c-suite. Kogan, who takes over with immediate effect, joins the company with a career spanning over 20 years in the life sciences sector. Previously, she served as the chief legal...
Verastem Gets FDA Orphan Drug Designation for Avutometinib With Defactinib to Treat Pancreatic Cancer
Verastem Gets FDA Orphan Drug Designation for Avutometinib With Defactinib to Treat Pancreatic Cancer
Jul 30, 2024
05:02 AM EDT, 07/30/2024 (MT Newswires) -- Verastem ( VSTM ) said Monday that the US Food and Drug Administration has granted orphan drug designation to avutometinib in combination with defactinib for the potential treatment of pancreatic cancer. This comes after the company reported positive initial interim results from the ongoing RAMP 205 trial evaluating avutometinib and defactinib in combination...
AXA IM Prime takes 20% stake in French private credit firm Rivage
AXA IM Prime takes 20% stake in French private credit firm Rivage
Jul 30, 2024
July 30 (Reuters) - AXA IM Prime, a unit of AXA Investment Managers, will acquire a 20% stake in French private credit firm Rivage Investment, the two companies said in a joint statement on Tuesday. Separately, AXA IM Prime, a long-standing investor in Rivage's strategies, will also put money in some of its infrastructure debt strategies, the companies said. Rivage...
Telefonica Brasil Q2 Earnings, Revenue Rise
Telefonica Brasil Q2 Earnings, Revenue Rise
Jul 30, 2024
04:50 AM EDT, 07/30/2024 (MT Newswires) -- Telefonica Brasil ( VIV ) reported late Monday Q2 earnings of 0.74 Brazilian reais ($0.13) per share, up from 0.68 reais a year earlier. A single analyst polled by Capital IQ expected 0.86 reais. Revenue for the quarter was 13.68 billion reais, up from 12.73 billion reais a year earlier. Analysts polled by...
Copyright 2023-2026 - www.financetom.com All Rights Reserved